• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, May 11, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI

Bioengineer by Bioengineer
January 24, 2023
in Health
Reading Time: 2 mins read
0
TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004155

TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI

Credit: Portnoy A, et al., 2023, PLOS Medicine, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004155

Article Title: The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

Author Countries: United States, United Kingdom, Netherlands, Switzerland, China

Funding: see manuscript



Journal

PLoS Medicine

DOI

10.1371/journal.pmed.1004155

Method of Research

Computational simulation/modeling

Subject of Research

Not applicable

COI Statement

Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Members of the funder (NG, MZ, SYS, RH, IGB, NN) participated as authors on the study and critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. All other authors have declared that no competing interests exist.

Share12Tweet8Share2ShareShareShare2

Related Posts

New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over 65 with Obesity, Regardless of Diabetes Status

May 11, 2026

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

May 10, 2026

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

May 10, 2026

Urdu Fall Risk Questionnaire Adapted for Elderly

May 10, 2026

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    840 shares
    Share 336 Tweet 210
  • New Study Reveals Plants Can Detect the Sound of Rain

    727 shares
    Share 290 Tweet 181
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    61 shares
    Share 24 Tweet 15
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over 65 with Obesity, Regardless of Diabetes Status

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.